Our work also demonstrates that targeting eIF2-α phosphorylation represents a novel pharmacological option to interfere with endotoxemia both by reducing liver damage and altering TLR4-dependent cytokine release. The gene discussed is TLR4; the disease is serum lipopolysaccharide activity.